Dr. Zhongxiao Wang received her MD and PhD degrees from Shanghai Jiaotong University, and experienced as exchange scholar at the University of Oklahoma, USA. She is currently a research scientist in Boston Children’s Hospital, Harvard Medical School. She is a member of the Association for Research in Vision and Ophthalmology (ARVO), and presents her work in the conference annually. She is also a member of the Longwood Translational Medicine, and reviewers of multiple international journals such as Plos One, Molecular Therapy, BMC Ophthalmology, Clinical Ophthalmology, Journal of Medical Case Reports and etc.

Dr. Wang’s research mainly focuses on the pathological angiogenesis of blinding eye diseases, including diabetic retinopathy (DR), age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and rare inherited eye diseases such as familial exudative vitreoretinopathy (FEVR) and Norrie disease. Dr. Wang dedicated her work to exploring novel interventions to prevent detrimental neovascularization progression through: (1) Regulating Wnt signaling pathway; (2) Manipulating circulating endothelial progenitor cells (EPC); (3) Developing small peptides derived from endogenous proteins to inhibit VEGF. Dr. Wang has published 7 peer-reviewed original papers on high ranking journals such as Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB), Investigative Ophthalmology and Visual Science, and Diabetes. Her work has been widely cited around the world and commented as one of the most influenced cover papers in ATVB.

Terms of Appointment: Jan. 1, 2017 - Dec. 31, 2019